Home Cart Sign in  
Chemical Structure| 2415-24-9 Chemical Structure| 2415-24-9

Structure of Catalpol
CAS No.: 2415-24-9

Chemical Structure| 2415-24-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Catalpol is a naturally occuring iridoid glucoside which exhibits anti-inflammatory activity and stimulates the production of adrenal cortical hormones.

Synonyms: Catalpinoside; 7,8-epoxy Aucubin; Digitalis purpurea L

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Catalpol

CAS No. :2415-24-9
Formula : C15H22O10
M.W : 362.33
SMILES Code : OC[C@@]12[C@]([C@@H]3O[C@]([C@@H]([C@@H](O)[C@@H]4O)O)([H])O[C@@H]4CO)([H])[C@](C=CO3)([H])[C@H](O)[C@@H]1O2
Synonyms :
Catalpinoside; 7,8-epoxy Aucubin; Digitalis purpurea L
MDL No. :MFCD11111524

Safety of Catalpol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
bone marrow mesenchymal stem cells (BMSCs) 10, 50, 250 μM 14 days To evaluate the effect of Catalpol on calcium deposition in BMSCs, results showed that Catalpol significantly increased calcium deposition. Stem Cell Res Ther. 2019 Jan 22;10(1):37
bone marrow mesenchymal stem cells (BMSCs) 10, 50, 250 μM 3 days To evaluate the effect of Catalpol on alkaline phosphatase (ALP) activity in BMSCs, results showed that Catalpol significantly enhanced ALP activity. Stem Cell Res Ther. 2019 Jan 22;10(1):37
bone marrow mesenchymal stem cells (BMSCs) 10, 50, 250 μM 1-5 days To evaluate the effect of Catalpol on the proliferation of BMSCs, results showed that Catalpol had no significant effect on the proliferation of BMSCs at these concentrations. Stem Cell Res Ther. 2019 Jan 22;10(1):37
Human umbilical vein endothelial cells (HUVECs) 100 μM 24 h Catalpol promoted HUVEC migration and tube formation via VEGF secreted by BMSCs. Stem Cell Res Ther. 2021 Feb 4;12(1):108
Rat bone marrow mesenchymal stem cells (BMSCs) 50, 100, 250 μM Catalpol enhanced osteogenic differentiation of BMSCs, as evidenced by increased ALP activity, enhanced calcium nodule formation, and upregulated expression of osteogenic-related proteins (COL1A1, RUNX2, OCN). Stem Cell Res Ther. 2021 Feb 4;12(1):108
brain microvascular endothelial cells (BMECs) and neural stem cells (NSCs) 25, 50, 100 μM 16 h To evaluate the protective effects of Catalpol on OGD-exposed 3D NVU. Results showed that Catalpol significantly improved the structure of 3D NVU after OGD exposure, reduced cell death, superoxide anion levels, and LDH leakage, and promoted vascular and neuronal protection. Acta Pharmacol Sin. 2022 Jul;43(7):1670-1685
Pre-myelinating oligodendrocytes (PreOLs) 0.5 mM 1 h Catalpol significantly reversed OGD-induced apoptosis and myelination deficits in PreOLs by inhibiting intracellular Ca2+ increase, reducing mitochondrial damage, and ameliorating overproduction of reactive oxygen species (ROS). Int J Biol Sci. 2016 Oct 26;12(12):1415-1426
AML12 cells 100-400 nM 36 h To evaluate the protective effects of CAT against TP-induced hepatocyte damage. Results showed that CAT pretreatment significantly reduced TP-induced increases in ALT, AST, and LDH activities, decreased ROS accumulation and lipid peroxidation, indicating that CAT alleviates TP-induced hepatotoxicity by improving oxidative stress and energy metabolism disorders. Int J Biol Sci. 2024 Aug 1;20(10):4077-4097
HEK 293T cells 10, 100 μM 24 h To investigate the inhibitory effect of Catalpol on TAK1 phosphorylation. Results showed that Catalpol inhibited TAK1 phosphorylation by binding to Asp-206, Thr-208, Asn-211, Glu-297, Lys-294, and Tyr-293 sites of TAK1. J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1306-1320
Human primary myoblasts 10, 30, 100 μM 24 h To investigate the inhibitory effect of Catalpol on TGF-β1-induced transdifferentiation of myoblasts into myofibroblasts. Results showed that Catalpol inhibited the phosphorylation of TAK1, reducing the expression of α-SMA and fibronectin, thereby suppressing the transdifferentiation of myoblasts into myofibroblasts. J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1306-1320

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Permanent middle cerebral artery occlusion model Intraperitoneal injection 5 mg/kg Once daily for 7 days Catalpol improved neurological function after stroke, promoted brain angiogenesis, upregulated EPO and VEGF expression, and did not worsen brain edema. Int J Biol Sci. 2010 Aug 20;6(5):443-53
Sprague-Dawley rats OVX-induced osteoporotic calvarial defect model Intraperitoneal injection 10 mg/kg Once daily for 8 weeks Catalpol promoted bone regeneration and angiogenesis in the calvarial defect area of OVX rats, as evidenced by increased bone volume, enhanced vessel area and number, and upregulated expression of osteogenic and angiogenic genes (RUNX2, OCN, VEGF). Stem Cell Res Ther. 2021 Feb 4;12(1):108
C57BL/6J mice TP-induced liver injury model Oral gavage 1.5, 3, and 4.5 mg/kg Once daily for two weeks To evaluate the protective effects of CAT against TP-induced liver injury. Results showed that CAT co-administration significantly alleviated TP-induced weight loss, increased liver index, and elevated serum ALT, AST, and LDH levels. Additionally, CAT improved liver histopathological changes and reduced levels of oxidative stress and lipid peroxidation markers (e.g., MDA and 4-HNE). Int J Biol Sci. 2024 Aug 1;20(10):4077-4097

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.76mL

0.55mL

0.28mL

13.80mL

2.76mL

1.38mL

27.60mL

5.52mL

2.76mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories